Clinical utility of MRI biomarkers for identifying NASH patients at high risk of progression: A multi-center pooled data and meta-analysis

Multicenter, biopsy-paired NAFLD analysis shows MRI PDFF and cT1 accurately identify NASH; cT1 better pinpoints patients at high risk of progression than liver fat alone. The data supports cT1 as a noninvasive biomarker for triage, risk stratification, and trial enrichment.